Source link : https://www.newshealth.biz/health-news/triplet-notches-survival-win-in-heavily-pretreated-dlbcl/
CHICAGO — A triplet combination consisting of the antibody-drug conjugate brentuximab vedotin (BV; Adcetris) plus lenalidomide (Revlimid) and rituximab for diffuse large B-cell lymphoma (DLBCL) improved survival in the third-line setting over lenalidomide-rituximab alone, an interim analysis of the phase III ECHELON-3 trial demonstrated. Among more than 200 patients receiving lenalidomide-rituximab, median overall survival (OS) […]
Author : News Health
Publish date : 2024-06-02 21:45:29
Copyright for syndicated content belongs to the linked Source.
Categories